ORPHA:504
Creeping myiasis
Also known as: Migratory myiasis
Publications
47
40th percentile
Trials
0
Interventional, condition-specific
Researchers
191
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
A rare cutaneous myiasis characterized by infestation of humans by the larvae of horse or cattle bot flies. After penetration of the skin, horse bot fly larvae form tunnels in the lower layers of the epidermis, where they can migrate for up to several months, causing serpentine, erythematous lesions with intense pruritus. Cattle bot fly larvae penetrate deeper into the subcutaneous tissue, producing more painful, erythematous lesions, which usually resolve after several hours or days, when the larvae move on to infest another area.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018857
- UMLS:C1562462
Additional Mondo synonyms (1)
migratory myiasis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
47 matched papers (24 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
47
47 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
47 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
24 in the last 10 years · high confidence · 40th percentile (publications denominator)
Phrase hits: 47 · MeSH hits: 0
Who's working on it?
191
Distinct author names in 47 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Kan B2 papers · 2017
Unit of Infectious Diseases, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Papers in Europe PMC - 02Sharma R2 papers · 2020
School of Public Health and Zoonoses, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, 141004 Punjab India.
Papers in Europe PMC - 03Aelbrecht M1 paper · 1990Papers in Europe PMC
- 04Agbor VN1 paper · 2018
Ibal sub-Divisional Hospital, Oku, North west Region, Cameroon.
Papers in Europe PMC - 05Agrawal S1 paper · 2017
Department of Parasitology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Papers in Europe PMC - 06Ahmed A1 paper · 2023
Institute of endemic diseases, University of Khartoum, Khartoum, Sudan.
Papers in Europe PMC - 07Akhoundi M1 paper · 2023
Parasitology-Mycology Department, Avicenne Hospital, AP-HP, Sorbonne Paris Nord University, 93000 Bobigny, France.
Papers in Europe PMC - 08Al-Mubarak LA1 paper · 2023
From the Department of Dermatology and Dermatology Surgery (Alsaedi, Al-Mubarak), and from the Department of Otolaryngology and Head and neck Surgery (Alqahtani), Prince Sultan Military Medical City, Riyadh, Kingdom of Saudi Arabia.
Papers in Europe PMC - 09Alarcón Plaza JT1 paper · 2025
General Practice, ESE Hospital San Francisco, Villa de Leyva, COL.
Papers in Europe PMC - 10Alqahtani MM1 paper · 2023
From the Department of Dermatology and Dermatology Surgery (Alsaedi, Al-Mubarak), and from the Department of Otolaryngology and Head and neck Surgery (Alqahtani), Prince Sultan Military Medical City, Riyadh, Kingdom of Saudi Arabia.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
Broader category myiasis also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Broader category: myiasis
0
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Parent-category matching found a broader label but no interventional trials under it. How we count trials.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Creeping myiasis" OR "Migratory myiasis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Creeping myiasis" OR "Migratory myiasis"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"myiasis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T14:04:43.612Z